Foscenvivint (ICG-001)

Catalog No.S2662

For research use only.

Foscenvivint (ICG-001) antagonizes Wnt/β-catenin/TCF-mediated transcription and specifically binds to CREB-binding protein (CBP) with IC50 of 3 μM, but is not the related transcriptional coactivator p300. ICG-001 induces apoptosis.

Foscenvivint (ICG-001) Chemical Structure

CAS No. 780757-88-2 (relative stereochemistry); 847591-62-2 (absolute stereochemistry)

Selleck's Foscenvivint (ICG-001) has been cited by 162 publications

Purity & Quality Control

Choose Selective Epigenetic Reader Domain Inhibitors

Biological Activity

Description Foscenvivint (ICG-001) antagonizes Wnt/β-catenin/TCF-mediated transcription and specifically binds to CREB-binding protein (CBP) with IC50 of 3 μM, but is not the related transcriptional coactivator p300. ICG-001 induces apoptosis.
Targets
CBP [1]
(Cell-free assay)
3 μM
In vitro

ICG-001 has no effect on the related reporter construct, FOPFLASH, which contains mutated TCF sites. After treatment with 25μM of ICG-001 for 8 hours, SW480 cell reduces the steady-state levels of Survivin and Cyclin D1 RNA and protein, both of which can be up-regulated by β-catenin. ICG-001 selectively induces apoptosis in transformed cells but not in normal colon cells, reduces in vitro growth of colon carcinoma cells. [1] ICG-001, can phenotypically rescue normal nerve growth factor (NGF) -induced neuronal differentiation and neurite outgrowth in the presenilin-1 mutant cells, emphasizing the importance of the TCF/β-catenin signaling pathway on neurite outgrowth and neuronal differentiation. [2] A recent study demonstrates that 5μM ICG-001 inhibits leptin-induced EMT, invasion and tumorsphere formation in MCF7 cells. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SH-SY5Y M3jNXWFxd3C2b4Ppd{BCe3OjeR?= NEXrb3E2OMLizszt MVGyOOKhcA>? MWfEUXNQ MmXEZoxw[2u|wrD0bIUheHKxdHXjeIl3\SCnZn\lZ5Qhd2ZibXXsZZRwdmmwIHHnZYlve3RiUILQJEgyODckgKOxNlYqNWmwZIXj[YQh[XCxcITveIlkKHOrZ37hcJM> M2PIZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkWxNFI5Lz5{NUK1NVAzQDxxYU6=
AsPC-1 NFvxfYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DqWlEuOjBizszN MUSyM|QwPiCm NUSzcVlTcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NHH1N2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC4Nlk3OCd-MkWwPFI6PjB:L3G+
MiaPaCa-2 MlW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvVU2JQOS1{MDFOwG0> MmDRNk81NzZiZB?= MUjpcohq[mm2czD0bIUh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M1vwe|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEiyPVYxLz5{NUC4Nlk3ODxxYU6=
PANC-1 NEHpO2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfDVZNXOS1{MDFOwG0> M4DPOlIwPC94IHS= M3yxO4lvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MlTiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyOEK5OlAoRjJ3MEiyPVYxRC:jPh?=
L3.6pl NX3nOFJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfBNU0zOCEQvF2= M4DTcFIwPC94IHS= M3TCXolvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M{HkOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEiyPVYxLz5{NUC4Nlk3ODxxYU6=
SH-SY5Y M3XIWGFxd3C2b4Ppd{BCe3OjeR?= MYWxNEDPxE1? MlHuNlQhcA>? M3;LfolvcGmkaYTzJJRp\SCwZYXyc5Bzd3SnY4TpeoUh\W[oZXP0d{Bw\iCqeYDvfIliKGGpYXnud5QhWHKSIDixNFYuOTJ4KT3t[YRq[XSnZDDu[ZVzd26jbDDj[YxtKGSnYYTo MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzlyMEW2Okc,OjN7MEC1OlY9N2F-
HKC-8  NHn3OG9HfW6ldHnvckBCe3OjeR?= NGjY[ncyOMLiwsXN NUX3SW9pOjRiaB?= MnHIZYJwdGm|aHXzxsDPui2lYYTlcolv6oDVbXXkbYF1\WRiUlHTJIlv\HWldHnvci=> MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTBzMkG2Okc,OjVyMUKxOlY9N2F-
HK-2  MnjJSpVv[3Srb36gRZN{[Xl? M4S3OFExKML3TR?= NFu4OZA{KGh? NUHkbFJbemWmdXPl[EB1cGViZYjwdoV{e2mxbjDv[kBVT0ZvzsKxMEDPuS2VTVGsJIFv\CCFVFfGJIFnfGW{IITy[YF1dWWwdDD3bZRpKEiKRR?= MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ7MEm5O{c,OjN4OUC5PVc9N2F-
HepT1 Mn7VRZBweHSxc3nzJGF{e2G7 MWOwMVExOMLizszN M2fZfFI1KGh? MmDkTWM2OD1|NNMg{txO NEXQV3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{K2OlcyQCd-MkOyOlY4OTh:L3G+
HuH6 MUnBdI9xfG:|aYOgRZN{[Xl? Mnf0NE0yODEEoN88US=> MVyyOEBp NYXTbFVkUUN3ME2zPeKh|ryP NILMSJo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{K2OlcyQCd-MkOyOlY4OTh:L3G+
MCF7 M4XucWZ2dmO2aX;uJGF{e2G7 MoDHOUDPxG4EoB?= MlPxbY5pcWKrdIOgcIVxfGmwLX3l[IlifGWmIHnuZ5Jm[XOnZDDlfJBz\XO|aX;uJI9nKFOwYXnsMEBUdHWpLDDhcoQhYmWkMh?= NXPmPWRLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyO|A{PTlpPkKyNlcxOzV7PD;hQi=>
RLE-6TN  MXrGeY5kfGmxbjDBd5NigQ>? MXyyMlUwPS95LkWg{txO MlHiOFghcA>? MlTJbY5pcWKrdIOgWGdHNc7{MT3pcoR2[2WmIN8xMXNOSSCrbnT1Z5Rqd25iYX7kJGVOXA>? MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ2MUS3PEc,OjJ{NEG0O|g9N2F-
HKC-8 NXPuOos4TnWwY4Tpc44hSXO|YYm= MYW1M|ExNzJyIN88US=> M3HVWlQ5KGh? MYficI9kc3NizsKtZ4F1\W6rbj3kdol3\W5iZ3Xu[UBmgHC{ZYPzbY9v NGXDVm49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUixOlk{Pyd-MkG4NVY6Ozd:L3G+
SW480 M2HjPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TTfVIuOTByIN88US=> MV;JR|UxRTVwONMxNE43QCEQvF2= NWi0Z2JIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUW3PFIyOzhpPkG1O|gzOTN6PD;hQi=>
SW480 NH;oSXFHfW6ldHnvckBie3OjeR?= NYfyU|c2UW6qaXLpeIlwdiCxZjDDRnAh[mmwZHnu[{B1dyCkZYThMYNie2WrbjDpckBpfW2jbjDTW|Q5OCClZXzsd{BjgSCrbX31co9jdG:2IHHuZYx6e2m|LDDJR|UxKD1iMT6zJO69VS5? Mlr1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{M{KwOlAoRjJ|MkOyNFYxRC:jPh?=
A549 NUj0SHVHSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NILldWs4OiCqcoO= M2e3TWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDHTVUxKD1iNj6xJO69VS5? MmKxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NUC0PFkoRjJ2OUWwOFg6RC:jPh?=
HepG2 Ml3JRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NV7nb3dWPzJiaILz M2L1OWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSHXwS|Ih[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygS2k2OCB;IEGyMlch|ryPLh?= M{i1ZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUWwOFg6Lz5{NEm1NFQ5QTxxYU6=
LoVo NGPzNY9CdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NYnm[5d{PzJiaILz M3zCUmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTH;Wc{Bk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDHTVUxKD1iMUWuOkDPxE1w NXjwNYI3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OVA1QDlpPkK0PVUxPDh7PD;hQi=>
HT-29 NHXVcXFCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NHLY[GY4OiCqcoO= M3jIeGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSGStNlkh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygS2k2OCB;IEG3MlIh|ryPLh?= NF7P[Hg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm1NFQ5QSd-MkS5OVA1QDl:L3G+
HT29 NGm4SWpHfW6ldHnvckBie3OjeR?= NG\FWY8zPCCqcoO= M4ru[GlvcGmkaYTpc44hd2ZiV370JJNq\26jbHnu[{BqdiCqdX3hckBJXDJ7IHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4Yh[mW2YT3jZZRmdmmwLX3l[IlifGWmIGTj[k9N\WZidILhcpNkemmydHnvcoFtKGGldHn2bZR6KGGodHXyJFI1KGi{czDifUBlfWGuIHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUBz\WyjdHn2[UB1dyClb370do9tNCCLQ{WwJF0hOThwNzFOwG0v M1iycVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUWwOFg6Lz5{NEm1NFQ5QTxxYU6=
TC32 M{i1N5FJXFNiYYPzZZk> NUXrd4c2eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGTDN|Ih[2WubIO= MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
A673 NVi1NGlReUiWUzDhd5NigQ>? Mlv3dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEF4N{OgZ4VtdHN? M2LMV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
DAOY M3:0VJFJXFNiYYPzZZk> MorndWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKESDT2mgZ4VtdHN? NWr3VmdSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-37 NUfNdZo2eUiWUzDhd5NigQ>? MXfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvM{egZ4VtdHN? MnKzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
RD NH63d3RyUFSVIHHzd4F6 M{TYO5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCURDDj[Yxtew>? MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
MG 63 (6-TG R) NUHRVphzeUiWUzDhd5NigQ>? MmfXdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE2JIE[zJEg3NVSJIGKpJINmdGy| MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
NB1643 NXrB[o86eUiWUzDhd5NigQ>? MUXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJzNkSzJINmdGy| NG\iW4Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
OHS-50 M3TMUJFJXFNiYYPzZZk> MlzrdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE:KUz21NEBk\Wyucx?= MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SJ-GBM2 MoHydWhVWyCjc4PhfS=> NG\qfFdyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1qtS2JOOiClZXzsdy=> NGjScJg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SK-N-MC MXnxTHRUKGG|c3H5 NHvT[HNyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1OSyClZXzsdy=> M3[1dlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB-EBc1 MoTBdWhVWyCjc4PhfS=> NWfucZlVeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF7CMWVD[zFiY3XscJM> NVKxOFA2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
LAN-5 NVvRZVl{eUiWUzDhd5NigQ>? MnTydWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEyDTj21JINmdGy| MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
LoVo MnHZR5l1d3SxeHnjbZR6KGG|c3H5 NX6zeZltOTBidV2= MkmwO|IhcHK| MWnDfZRwfG:6aXPpeJkh[WejaX7zeEBYdnRxYnX0ZU1k[XSnbnnuJJNq\26jbHzpcoch\GWyZX7k[Y51KGi3bXHuJGxwXm9iY3XscJMh[XO|ZYPz[YQh[XNiY3XscEB3cWGkaXzpeJkh[XRiMUCgeW0h[W[2ZYKgO|IhcHK|IHL5JGFVWGyrdHWgZZN{[Xl? M{n5U|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI{OTJzM{mvK|5EcEWPQly8M4E,
NCI-H1703 M{TOXWZ2dmO2aX;uJIF{e2G7 NXvHUWFTOTBidV2= NV3IPZJ5OjRiaILz MoD3TY5pcWKrdHnvckBw\iCWTlnLJIlvKGi3bXHuJG5EUS2KMUewN{Bk\WyuczD0doFve2[nY4Tl[EB4cXSqIHzlcpRqfmm{YXygeoVkfG:{IEfUSnAh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIH;mJGdUUzNiaX7obYJqfG:{IGigZYN1cX[jdHXkJHRPUUtvbXXkbYF1\WRiV370M3RETi:kZYThMYNifGWwaX6t[IVx\W6mZX70JJRz[W6|Y4LpdJRqd25iYYSgNVAhfU1iYX\0[ZIhOjRiaILzJIJ6KGy3Y3nm[ZJie2VicnXwc5J1\XJiYYPzZZk> MkL6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlMyOjF|OT:nQmNpTU2ETEyvZV4>
HCT116 NIPibmFEgXSxdH;4bYNqfHliYYPzZZk> M4j2UlExKHWP Ml;DO|IhcHK| NUXSeGZvS3m2b4TvfIlkcXS7IHHnZYlve3RiV370M4JmfGFvY3H0[Y5qdiC|aXfuZYxtcW6pIHTldIVv\GWwdDDoeY1idiCKQ2SxNVYh[2WubIOgZZN{\XO|ZXSgZZMh[2WubDD2bYFjcWyrdImgZZQhOTBidV2gZYZ1\XJiN{KgbJJ{KGK7IFHUVIxqfGViYYPzZZk> MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyN|EzOTN7Lze+R4hGVUKOPD;hQi=>
Assay
Methods Test Index PMID
Western blot CCNB1 / Cyclin D1 ; ABC / Beta-catenin / E-cadherin / N-cadherin / MMP-9 / c-MYC / Actin / Histone H3 ; beta-catenin / F-actin ; pβ-catenin ; SOX-2 / CD44 / Survivin / EGFR / FOXM1 / EZH2 / Vimentin 28893318 29986466 25897700
In vivo Administration of a water-soluble analog of ICG-001 for 9 weeks reduces the formation of colon and small intestinal polyps by 42% as effectively as the nonsteroidal antiinflammatory agent Sulindac, which has consistently demonstrated efficacy in this model. No overt toxicity is detected throughout the course of treatment. In the SW620 nude mouse xenograft model of tumor regression, 150 mg/kg, i.v. of analog demonstrates a dramatic reduction in tumor volume over the 19-day course of treatment, with no mortality or weight loss. [1] ICG-001 (5 mg/kg per day) significantly inhibits beta-catenin signaling and attenuates bleomycin-induced lung fibrosis in mice, while concurrently preserving the epithelium. [4]

Protocol (from reference)

Kinase Assay:[1]
  • DUAL-Luciferase Reporter Assay:

    The Dual-Luciferase Reporter (DLR) Assay System provides an efficient means of performing dual reporter assays. In the DLRTM Assay, the activities of firefly (Photinus pyralis) and Renilla (Renilla reniformis, also known as sea pansy) luciferases are measured sequentially from a single sample. The firefly luciferase reporter is measured first by adding Luciferase Assay Reagent II (LAR II) to generate a “glow-type” luminescent signal. After quantifying the firefly luminescence, this reaction is quenched, and the Renilla luciferase reaction is initiated by simultaneously adding Stop & Glo® Reagent to the same tube. The Stop & Glo® Reagent also produces a “glow-type” signal from the Renilla luciferase, which decays slowly over the course of the measurement. In the DLRTM Assay System, both reporters yield linear assays with subattomole (<10-18) sensitivities and no endogenous activity of either reporter in the experimental host cells. Furthermore, the integrated format of the DLRTM Assay provides rapid quantitation of both reporters either in transfected cells or in cell-free transcription/translation reactions.

Cell Research:[1]
  • Cell lines: Human colon carcinoma cell lines SW480, SW620, and HCT116, normal colonic epithelial cell line CCD-841Co
  • Concentrations: ~25 μM
  • Incubation Time: 24 hours
  • Method: 1. Prior to starting the assay, prepare the Apo-ONE Caspase-3/7 Reagent, and mix thoroughly. 2. For best results, empirical determination of the optimal cell number, apoptosis induction treatment and incubation period for the cell culture system may be necessary. 3. Use identical cell numbers and volumes for the assay and the negative control samples. 4. Do not mix Apo-ONE Caspase-3/7 Reagent and samples by manual pipetting. Mixing in this manner is unnecessary and may create bubbles that interfere with fluorescence readings or cross-contaminate the samples. Gentle mixing may be performed using a plate shaker. 5. Total incubation time for the assay depends upon the amount of caspase- 3/7 present in the sample. 6. The Apo-ONE Caspase-3/7 Reagent is formulated to mediate cellular lysis and support optimal caspase-3/7 activity. In rare instances, the reagent does not affect complete lysis of cultured cells. In such cases, lysis is enhanced by a freeze-thaw cycle. For best results, freeze at -70 °C, then thaw at room temperature. After equilibration, mix to homogeneity and incubate until measurable fluorescence is achieved
Animal Research:[1]
  • Animal Models: Seven-week-old male C57BL/6J-Apc Min/+
  • Dosages: 300 mg/kg
  • Administration: Water-soluble analog of ICG-001 is treated orally for 9 weeks everyday.

Solubility (25°C)

In vitro

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
2% DMSO+50% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.

5mg/mL

Chemical Information

Molecular Weight 548.63
Formula

C33H32N4O4

CAS No. 780757-88-2 (relative stereochemistry); 847591-62-2 (absolute stereochemistry)
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C1CN(C2CN(C(=O)C(N2C1=O)CC3=CC=C(C=C3)O)CC4=CC=CC5=CC=CC=C54)C(=O)NCC6=CC=CC=C6

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Frequently Asked Questions

Question 1:
If the compound is stored in DMSO at -80, how long would it be stable? For cell culture, how long should I change for the fresh medium with ICG-001?

Answer:
The product in DMSO solution can be stored at 4 degree for 1 week and -20 degree for 1 month. The best storage condition is solid powder, even at -80 the solution is not stable enough for long term storage. For cell culture, you need change medium every 48h.

Tags: buy Foscenvivint (ICG-001) | Foscenvivint (ICG-001) supplier | purchase Foscenvivint (ICG-001) | Foscenvivint (ICG-001) cost | Foscenvivint (ICG-001) manufacturer | order Foscenvivint (ICG-001) | Foscenvivint (ICG-001) distributor